Hematopoietic Cell Transplantation for Epithelial Ovarian Cancer

Policy # 00054
Original Effective Date: 01/28/2002
Current Effective Date: 06/21/2017

Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers autologous and allogeneic hematopoietic cell transplantation (HCT) to treat epithelial ovarian cancer to be investigational.*

Background/Overview
EPITHELIAL OVARIAN CANCER
Several types of malignancies can arise in the ovary; epithelial carcinoma is the most common. Epithelial ovarian cancer is the fifth most common cause of cancer death in women. New cases and deaths from ovarian cancer in the United States for 2016 were estimated at 22,280 and 14,240, respectively. Most ovarian cancer patients present with widespread disease, and annual mortality is approximately 65% of the incidence rate.

Current management for advanced epithelial ovarian cancer is cytoreductive surgery with chemotherapy. Approximately 75% of patients present with International Federation of Gynecology and Obstetrics stage III to IV ovarian cancer and are treated with paclitaxel plus a platinum analogue, the preferred regimen for newly diagnosed advanced disease. Use of platinum and taxanes has improved progression-free survival and overall survival in advanced disease to between 16 and 21 months and 32 and 57 months, respectively. However, cancer recurs in most women and they die of the disease, because chemotherapy drug resistance leads to uncontrolled cancer growth.

HEMATOPOIETIC CELL TRANSPLANTATION
Hematopoietic cell transplantation is a procedure in which hematopoietic stem cells are infused to restore bone marrow function in cancer patients who receive bone-marrow-toxic doses of drugs with or without whole body radiotherapy. Bone marrow stem cells may be obtained from the transplant recipient (autologous HCT) or from a donor (allogeneic HCT). They can be harvested from bone marrow, peripheral blood, or umbilical cord blood and placenta shortly after delivery of neonates. Although cord blood is an allogeneic source, the stem cells in it are antigenically “naïve” and thus are associated with a lower incidence of rejection or graft-versus-host disease.

Hematopoietic cell transplantation is an established treatment for certain hematologic malignancies; however, its use in solid tumors in adults is largely experimental.
Hematopoietic Cell Transplantation for Epithelial Ovarian Cancer

Hematopoietic cell transplantation has been investigated as a therapy to overcome drug resistance. However, limited data exist on this treatment approach; the ideal patient population and best treatment regimen remain to be established. HCT has been tested in various patient groups with ovarian cancer:

- To consolidate remission after induction therapy
- To treat relapse after a durable response to platinum-based chemotherapy
- To treat tumors that relapse after less than 6 months
- To treat refractory tumors.

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)
The U.S. FDA regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation (CFR) title 21, parts 1270 and 1271. Hematopoietic stem cells are included in these regulations.

Centers for Medicare and Medicaid Services (CMS)
The Centers for Medicare and Medicaid Services currently have the following national noncoverage decision on autologous stem cell transplantation [AuSCT]: “Insufficient data exist to establish definite conclusions regarding the efficacy of AuSCT for the following condition[s]: Solid tumors (other than neuroblastoma).”

Rationale/Source

HEMATOPOIETIC CELL TRANSPLANTATION FOR EPITHELIAL OVARIAN CANCER
This evidence review was originally based on a 1998 TEC Assessment that reached the following conclusions:

- Data were unavailable from randomized controlled trials for any of the patient groups studied. Thus, the Assessment was able to compare outcomes only indirectly, using separate studies of high-dose chemotherapy (HDC) and conventional dose regimens. Although some results reported after HDC appeared encouraging, indirect comparisons did not permit conclusions.
- In previously untreated patients, reported response rates suggested that HDC increased objective response rates compared with patients given conventional-dose chemotherapy. However, this comparison was flawed by age bias and by differences in performance status and other baseline characteristics of patients included in the 2 sets of studies. Response duration and survival data were unavailable for comparison. Treatment-related mortality was greater after HDC.
- In previously treated patients, objective response rates after HDC also were reportedly higher than after conventional-dose regimens. Subgroup analyses showed higher response rates among platinum-sensitive, optimally debulked patients. Minimum values of the ranges reported across studies for median response duration and survival after HDC were similar to those reported after conventional-dose chemotherapy. However, the maxima for these ranges suggested improved response duration and overall survival (OS) after HDC. In contrast, data from the Autologous Blood and Marrow Transplant Registry did not show similarly high survival for comparable subgroups. Comparison with conventional-dose chemotherapy was again biased due to differences in age
Hematopoietic Cell Transplantation for Epithelial Ovarian Cancer

Policy # 00054
Original Effective Date: 01/28/2002
Current Effective Date: 06/21/2017

The 1998 TEC Assessment did not identify any studies reporting outcomes of allogeneic transplants for patients with ovarian cancer. A separate 1999 TEC Assessment evaluated the use of HDC with allogeneic stem cell support as salvage therapy after a failed prior course of HDC with autologous stem cell support. There were no data on outcomes of this strategy as therapy for epithelial ovarian cancer.

Experience with HCT in epithelial ovarian cancer is primarily derived from registry data and phase 2 trials. Many registry patients were treated after relapse and others in nonrandomized trials using HDC as first-line treatment. Case selection and retrospective review make interpretation of registry and nonrandomized data difficult. Survival analyses from registry data and clinical trials have suggested a possible benefit in treating ovarian cancer patients with HCT.

Randomized Controlled Trials
In 2007, Mobus et al reported on a randomized, phase 3 trial that included 149 patients with untreated ovarian cancer who were randomized, after debulking surgery, to standard chemotherapy or sequential HDC and peripheral blood stem cell support. This was the first randomized trial comparing HDC with standard chemotherapy as first-line treatment of ovarian cancer, and investigators found no statistically significant differences in progression-free survival (PFS) or OS between the 2 treatments. The study was powered such that a sample of 208 patients would be needed to detect an absolute improvement of 15% in PFS with a power of 80% and a 1-sided \( \alpha \) of 5%. Median patient age was 50 years (range, 20–65 years) and International Federation of Gynecology and Obstetrics (FIGO) stage was IIB or IIC in 4%, stage III in 78%, and stage IV in 17%. Seventy-six percent of patients in the HDC arm received all scheduled chemotherapy cycles. After a median follow-up of 38 months, PFS was 20.5 months in the standard chemotherapy arm and 29.6 months in the HDC arm (hazard ratio [HR], 0.84; 95% confidence interval [CI], 0.56 to 1.26; \( p = 0.40 \)). Median OS was 62.8 months in the standard chemotherapy arm and 54.4 months in the HDC arm (HR=1.17; 95% CI, 0.71 to 1.94; \( p = 0.54 \)).

In 2008, Papadimitriou et al reported on an RCT comparing the use of HDC with stem cell support as consolidation therapy in patients with advanced epithelial ovarian cancer (FIGO stage IIC-IV). Patients who achieved first complete remission after conventional chemotherapy were randomized to receive or not high-dose melphalan and autologous HCT. Eighty patients were enrolled in the trial. Of 37 patients allocated to HDC, 11 (30%) did not receive the treatment either due to refusal or failure of peripheral blood stem cell mobilization. In an intention-to-treat analysis, there were no significant differences between the 2 arms in time-to-disease progression (\( p = 0.059 \)) or OS (\( p = 0.38 \)).

Observational Comparative Studies
In 2012, Sabatier et al retrospectively reviewed 163 patients with advanced or metastatic (FIGO stage IIIC or IV) epithelial ovarian cancer who were treated at a single institution in France. All patients received cytoreductive surgery and combination platinum plus taxane chemotherapy. Investigators compared median PFS and OS between 60 patients who received subsequent HDC with autologous HCT support and 103 patients who did not. HDC regimens varied, but all contained alkylating agents. At a median follow-up of 47.5 months, PFS in the high-dose and the standard chemotherapy groups was 20.1 and 18.1 months,
Hematopoietic Cell Transplantation for Epithelial Ovarian Cancer

Policy # 00054
Original Effective Date: 01/28/2002
Current Effective Date: 06/21/2017

respectively (p not reported). OS was 47.3 and 41.3 months, respectively (p=0.29). In prespecified subgroup analyses, median PFS was significantly longer in women younger than age 50 years who received HDC (81.7 months) than in women who received standard chemotherapy (11 months; p=0.02); in women older than 50 years, median PFS did not differ statistically between groups (17.9 months vs 18.3 months, respectively; p=0.81). Similarly, median OS was significantly longer in women younger than age 50 years who received HDC (54.6 months) than in women who received standard chemotherapy (36 months; p=0.05), but not in women older than 50 years (49.5 months vs 42 months, respectively; p not reported). The authors recommended further study of HDC with autologous HCT support in patients younger than 50 years.

SUMMARY OF EVIDENCE
For individuals who have advanced-stage epithelial ovarian cancer who receive HCT, the evidence includes randomized trials and data from case series and registries. Relevant outcomes are overall survival, disease-specific survival, change in disease status, and treatment related mortality and morbidity. Although some observational studies have reported longer survival in subsets of women with advanced epithelial ovarian cancer than in women treated with standard chemotherapy, none of the randomized trial evidence has shown an benefit from HCT in this population. Overall, the evidence has not shown that HCT improves health outcomes in treating epithelial ovarian cancer, including survival, compared with conventional standard doses of chemotherapy. The evidence is insufficient to determine the effects of the technology on health outcomes.

References
Hematopoietic Cell Transplantation for Epithelial Ovarian Cancer

Policy # 00054
Original Effective Date: 01/28/2002
Current Effective Date: 06/21/2017


Policy History
Original Effective Date: 01/28/2002
Current Effective Date: 06/21/2017

12/06/2001 Medical Policy Committee review.
01/28/2002 Managed Care Advisory Council approval.
05/07/2004 Medical Director review
05/18/2004 Medical Policy Committee review. High-Dose Chemotherapy and Hematopoietic Stem Cell Support for treatment of ovarian epithelial cancer policy developed separately from current HDC with Hematopoietic Stem Cell Support policy. Format revision. No substance change to policy.
06/28/2004 Managed Care Advisory Council approval
07/07/2006 Format revision, including addition of FDA and or other governmental regulatory approval and rationale/source. Coverage eligibility unchanged.
08/02/2006 Medical Director Review
08/09/2006 Medical Policy Committee approval
08/06/2008 Medical Director Review
08/20/2008 Medical Policy Committee approval. No change to coverage eligibility.
08/06/2009 Medical Policy Committee approval
12/01/2010 Medical Policy Committee approval
12/15/2010 Medical Policy Implementation Committee approval. Coverage eligibility unchanged
12/08/2011 Medical Policy Committee review
12/06/2012 Medical Policy Committee review
12/19/2012 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
03/04/2013 Coding update
12/12/2013 Medical Policy Committee review
12/18/2013 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
06/04/2015 Medical Policy Committee review
06/17/2015 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/03/2015 Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
06/02/2016 Medical Policy Committee review
06/20/2016 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
01/01/2017 Coding update: Removing ICD-9 Diagnosis Codes
06/01/2017 Medical Policy Committee review
06/21/2017 Medical Policy Implementation Committee approval. Removed the word “Stem” from title and policy.
11/15/2017 Coding update
Next Scheduled Review Date: 6/2018

Coding
The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2016 by the American Medical Association (AMA). CPT

©2017 Blue Cross and Blue Shield of Louisiana
An independent licensee of the Blue Cross and Blue Shield Association
No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.

Page 5 of 6
Hematopoietic Cell Transplantation for Epithelial Ovarian Cancer

Policy # 00054
Original Effective Date: 01/28/2002
Current Effective Date: 06/21/2017

is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>38204, 38205, 38206, 38207, 38208, 38209, 38210, 38211, 38212, 38213, 38214, 38215, 38230, 38240, 38241, 38242, 38243</td>
</tr>
<tr>
<td>HCPCS</td>
<td>S2140, S2142, S2150</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>C56.1-C56.9, C57.00-C57.02, C57.10-C57.12, C57.20-C57.22, C57.3-C57.4</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

   A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. FDA and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
   B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

      1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
      2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
      3. Reference to federal regulations.

†† Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.